Watertown-based Ingenia Therapeutics received $5 million in funding from a single investor, according to a recent filing.
The startup is targeting an equity offering with $25 million total value, according to a regulatory filing with U.S. Securities and Exchange Commission dated June 21.
The company did not respond to a request for comment on Monday.
Sangyeul Han, a Ph.D. graduate in cell biology from the University of Seoul, co-founded Ingenia in 2019 after five years as a senior scientist at the Samsung Advanced Institute for Technology.
Ingenia last raised funding with $7 million as part of an equity offering worth $16 million, according to a Form D dated Nov. 30, 2022. Prior to that, the startup raised $4.7 million as part of an equity offering worth $5,707,530, through nine investors, according to a Form D filed on Sept. 29, 2020.
Ingenia aims to heal endothelial cells, which comprise the layer between the bloodstream and surrounding tissues. It plans to develop antibodies that can restore dysfunctional microvessels to a healthier state.
A wide range of diseases impact blood vessels, making them hard to treat and manage. Ingenia Therapeutics is trying to help fix leaky or damaged blood vessels to make diseases like the vascular complications of diabetes, retinal diseases, inflammatory diseases, cancer, and vasculitis easier to manage.
